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Abstract
Effective empirical treatment is of paramount importance to improve the outcome of patients with Staphylococcus aureus bacteraemia. We
aimed to evaluate a PCR-based rapid diagnosis of methicillin resistance (GeneXpert MRSA) after early detection of S. aureus bacteraemia
using matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS). Patients with a ﬁrst episode of
S. aureus bacteraemia identiﬁed using MALDI-TOF MS were randomized in a prospective interventional open study between October 2010
and August 2012. In the control group, antibiotic susceptibility testing was performed after MALDI-TOF MS identiﬁcation on blood culture
pellets. In the intervention group, a GeneXpert MRSA was performed after S. aureus identiﬁcation. The primary outcome was the
performance of GeneXpert MRSA directly on blood cultures. We then assessed the impact of early diagnosis of methicillin resistance on the
empirical treatment. In all, 197 episodes of S. aureus bacteraemia were included in the study, of which 106 were included in the intervention
group. Median time from MALDI-TOF MS identiﬁcation to GeneXpert MRSA result was 97 min (range 25–250). Detection of methicillin
resistance using GeneXpert MRSA had a sensitivity of 99% and a speciﬁcity of 100%. There was less unnecessary coverage of MRSA in the
intervention group (17.1% versus 29.2%, p 0.09). GeneXpert MRSA was highly reliable in diagnosing methicillin resistance when performed
directly on positive blood cultures. This could help to avoid unnecessary prescriptions of anti-MRSA agents and promote the introduction of
earlier adequate coverage in unsuspected cases.
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Introduction
Staphylococcus aureus is a major cause of community-acquired
and nosocomial bacteraemia [1,2]. The associated mortality,
which ranges from 15 to 60%, is higher in cases of methicil-
lin-resistant S. aureus (MRSA) [3,4]. Early introduction of
appropriate empirical antibiotic therapy improves the outcome
of patients with S. aureus bacteraemia [5,6].
Although Gram staining of positive blood cultures has a high
impact on empirical antibiotic therapy [7], deﬁnitive identiﬁ-
cation of the aetiological agent and determination of its
antibiotic susceptibility may imply a delay of 24–48 h. Empirical
antibiotic therapy is based on clinical assessment and epide-
miological setting. In the case of positive blood cultures with
gram-positive cocci in clusters, empirical coverage of MRSA
may be automatic in high-prevalence settings. Wider use of
vancomycin or new anti-gram-positive antibiotics may cause
unnecessary costs and toxicity, and favour the development of
resistance.
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Matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) was prospectively
assessed for the rapid diagnosis of bloodstream infections
[8–12]. Our experience of bacterial identiﬁcation by MAL-
DI-TOF MS on positive blood culture pellets after an
ammonium chloride erythrocyte-lysing procedure led to the
correct identiﬁcation at species level of 79% of tested pellets
and, more speciﬁcally, all 25 episodes of S. aureus bacteraemia
were correctly identiﬁed with a score ≥1.7, theoretically
indicating an identiﬁcation that is reliable at genus level only
[9]. Other groups also conﬁrmed high performances of
S. aureus identiﬁcation in blood cultures using MALDI-TOF
MS [10–12]. Although the early identiﬁcation of S. aureus is
possible with MALDI-TOF MS, the time to obtaining
antibiotic susceptibility results (AST) remains unchanged.
The identiﬁcation of methicillin resistance using MALDI-TOF
MS remains experimental without clinical validation to date
[13,14].
Tests based on PCR and targeting the mecA gene for the
identiﬁcation of MRSA were used at ﬁrst for the rapid
diagnosis of MRSA carriage with the aim of preventing its
nosocomial transmission [15]. This technique applied to
positive blood cultures with gram-positive cocci in clusters
showed a high sensitivity of 96–100% for the detection of
MRSA [16–18]. As a routine procedure, it would generate high
costs because of the frequency of coagulase-negative staphy-
lococci in blood cultures. In our centre, 1020 bottles of blood
cultures returned positive for coagulase-negative staphylococci
during the study period.
In this pilot study, we aimed to test the combination of early
detection of S. aureus using MALDI-TOF MS with a PCR-based
detection of methicillin resistance in blood cultures. We tested
the accuracy of this method to detect the resistance to
methicillin based on subsequent antibiotic susceptibility results
in the setting of an innovative combined diagnostic of S. aureus
bacteraemia. We also wanted to assess the consequences of
early PCR-based identiﬁcation of methicillin resistance regard-
ing empirical antibiotic therapy and particularly the prescrip-
tion of unnecessary MRSA coverage.
Materials and Methods
Design and case deﬁnition
Patients with a ﬁrst episode of S. aureus bacteraemia identiﬁed
using MALDI-TOF MS were included in a prospective,
randomized open study between October 2010 and August
2012 in Lausanne University Hospital Centre, an 850-bed
primary and tertiary care hospital in western Switzerland
where S. aureus resistance to methicillin was 23% in 2010 and
indications for MRSA screening were extended after a
hospital-wide outbreak in 2008. We excluded cases with
known antibiotic susceptibility results (e.g. transfers from
other hospitals) and patients who were dead at time of
diagnosis of bacteraemia. Randomization was performed using
a unique number assigned to each hospitalized patient in our
centre, which was not linked to patient characteristics. In the
control group (odd number), standard AST was performed
after MALDI-TOF MS identiﬁcation (time to antibiotic sus-
ceptibility result of about 24–48 h). In the intervention group
(even number), MALDI-TOF MS identiﬁcation was coupled to
a GeneXpert MRSA test (Cepheid, Sunnyvale, CA, USA)
performed directly on positive blood culture pellets, in
addition to standard AST. Mode of randomization was
concealed from the clinicians. We planned to include around
100 cases in the intervention group to assess the performances
of GeneXpert in the setting of this combined diagnostic of
S. aureus bacteraemia. For each case, a standardized case
report form including epidemiological, clinical and biological
data, as well as the sequence of empirical antibiotic therapy,
was ﬁlled in.
Procedures
Positive blood cultures were detected using the BACTEC
9240 automated blood culture system (Becton Dickinson,
Sparks, MD, USA). Direct MALDI-TOF MS has been per-
formed routinely in our centre on all positive blood cultures
since September 2009. Mass spectra were acquired on a
Microﬂex LT MALDI-TOF MS (Bruker Daltonics, Bremen,
Germany) after a standardized ammonium chloride erythro-
cyte-lysing procedure [9]. Spectral analysis and comparison
with the database were carried out using MALDI BIOTYPER 2.0
software. Identiﬁcation of S. aureus on positive blood cultures
with gram-positive cocci in clusters was considered adequate
when the score value was ≥1.7 [9]. In the control group, Gram
stain and MALDI-TOF MS results were sequentially reported
orally to clinicians during working hours (0800–1700 h) as well
as electronically using the laboratory information system.
Clinicians were contacted the following day for blood cultures
that turned positive out of hours. AST was started concom-
itantly. In the intervention group, the same procedure was
followed; in addition, a PCR-based rapid test targeting spa,
mecA and SCC genes (GeneXpert MRSA) was immediately
launched on the blood culture pellets. Clinicians were told of
this ongoing test when informed of the S. aureus bacteraemia.
The result of GeneXpert MRSA was then provided orally
during daytime hours as well as electronically using a
standardized recall of previously issued test result data
[16,18]. An infectious diseases consultation was recommended
in all cases of S. aureus bacteraemia.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 355–360
356 Clinical Microbiology and Infection, Volume 20 Number 4, April 2014 CMI
Study deﬁnitions and outcomes
Adequacy of empirical antibiotic therapy was deﬁned as the
prescription of an active antibiotic, as conﬁrmed by AST
performed on subcultures. Adequacy of empirical antibiotic
therapy (MALDI-TOF MS-directed treatment) was assessed
similarly for both groups after informing the clinician of the
S. aureus bacteraemia, secondarily to MALDI-TOF MS iden-
tiﬁcation, as this corresponded to the time of intervention
and allowed us to test the impact of the immediate
GeneXpert availability on the choice of empirical treatment.
Glycopeptides and daptomycin were considered appropriate
for MRSA bacteraemia. Drugs with activity against methicil-
lin-susceptible S. aureus (MSSA), adequate dosing for bacter-
aemia and intravenous administration were considered
appropriate treatments for MSSA bacteraemia. Immunosup-
pression included neutropenia, HIV infection and immuno-
suppressive drugs. Bacteraemia cases were considered
nosocomial if blood cultures were taken ≥48 h after hospital-
ization, and complicated if local or metastatic complications
occurred during follow up. Penicillin allergy was deﬁned based
on the medical record. Severe sepsis/septic shock were deﬁned
according to standard deﬁnitions [19]. Renal insufﬁciency was
deﬁned as an increase from baseline creatinine value of >50%
and was evaluated at day 3, 7 and 14. The ﬁrst outcome was
the accuracy of GeneXpert MRSA to detect the resistance to
methicillin based on subsequent AST. We secondarily wanted
to assess the consequences regarding MRSA coverage.
Statistics
Categorical variables were compared using the chi-squared or
Fisher’s exact tests when appropriate; continuous variables
were compared using Mann–Whitney U test. Analyses were
conducted using GRAPHPAD PRISM software version 5.03
(GraphPad, San Diego, CA, USA). A p value of ≤0.05 was
considered signiﬁcant.
Results
There were 224 episodes of S. aureus bacteraemia during the
study period (Fig. 1). During this period, 5622 blood culture
bottles returned positive results. Twelve episodes were
excluded as failures of MALDI-TOF MS identiﬁcation, of
which nine were polymicrobial bacteraemia. False
identiﬁcations of S. aureus (identiﬁcation score ≥1.7) did not
occur during the study period. Four additional episodes were
excluded because they occurred during the weekend initially.
Altogether, 208/220 episodes of S. aureus bacteraemia (94.5%
of all tested) were correctly identiﬁed by MALDI-TOF MS
(identiﬁcation score ≥1.7) and 197 were included in the
study. Using the numbers assigned to each patient at hospital
admission, 106 patients were assigned to the intervention
group and 91 to the control group.
Patient characteristics
Although randomization led to unequal numbers, the groups
were well balanced in their epidemiological and clinical
characteristics (Table 1). In particular, 94% of all empirical
antibiotic therapies were considered adequate in both groups.
Of 197 episodes of bacteraemia, 43 (21.8%) were due to
MRSA. In both groups, the most frequent sources of bacter-
aemia were intravascular catheters and skin/soft tissue infec-
tions. An unknown origin of infection was more frequent in the
control group (p 0.04).
224 episodes of SAB 
during the study period 
9 deaths at diagnosis 
12 failures of MALDI-TOF MS
identification (9 polymicrobial) 
4 excluded during the weekend
2 transfers from others hospitals 
with known antibiotic susceptibility 
197 SAB 
91 control group 106 intervention group
ASTAST
GenXpertFIG. 1. Study ﬂow chart showing the exclu-
sion criteria and randomization. SAB, Staphylo-
coccus aureus bacteraemia; AST, antibiotic
susceptibility testing.
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Performance of GeneXpert MRSA and MALDI-TOF MS
In the intervention group, a correct identiﬁcation of methicillin
susceptibility was possible in 105/106 cases. There were 24
episodes of MRSA bacteraemia and 82 episodes of MSSA
bacteraemia. For the only case of MSSA bacteraemia with an
undetermined result, repetition of GeneXpert led to a correct
result. There was no false-positive detection of resistance to
methicillin. Considering the indeterminate result initially
obtained as a false-negative, a sensitivity of 99% and a
speciﬁcity of 100% were therefore measured for the detection
of methicillin resistance on positive blood culture pellets with
gram-positive cocci in clusters identiﬁed as S. aureus with
MALDI-TOF MS.
Identiﬁcation of S. aureus with MALDI-TOF MS as evaluated
on 220 episodes had a sensitivity of 94.5% and a speciﬁcity of
100%, as no specimen was wrongly identiﬁed as S. aureus by
MALDI-TOF MS during the study. The 5.5% of S. aureus not
identiﬁed by MALDI-TOF MS all exhibited scores <1.7; hence,
no false identiﬁcation occurred when the score was ≥1.7. No
S. aureus was wrongly identiﬁed as another species during the
study.
Time to result
There were 65/106 episodes (61.3%) that led to direct telephone
transmission ofMALDI-TOFMS identiﬁcation of S. aureus and/or
GeneXpert result to the clinician in the intervention group.Other
cases were transmitted only by the laboratory information
system, because they occurred out of hours. The median time
from MALDI-TOF MS identiﬁcation to GeneXpert result (56
evaluable episodes) was 97 min (range 25–250). Median time
from blood culture positivity to GeneXpert result (57 evaluable
episodes) was 201 min (range 100–430).
Impact on empirical antibiotic therapy
As shown in Table 1, both groups had similarly high degrees of
initial adequacy of empirical antibiotic therapy (94%) as
conﬁrmed by AST. Among the 43 patients with MRSA
bacteraemia, 34 (79.1%) were previously known MRSA
carriers, so >90% of patients with MRSA bacteraemia received
an empirical coverage of MRSA in both groups. There was less
unnecessary use of glycopeptides for MSSA in the intervention
group, although this difference did not reach statistical
signiﬁcance (17.1% versus 29.2%, p 0.09). When excluding
patients with penicillin allergy, who were over-represented in
the intervention group (10/106, 9.4% versus 5/91, 5.5%,
Table 1), the rate of unnecessary use of glycopeptides for
MSSA decreased from 26.1% (18/69) in the control group to
only 8.1% (6/74) in the intervention group (p <0.01). For the
two patients in the intervention group that did not receive an
early coverage of MRSA, rapid detection of MRSA with
GeneXpert allowed an early coverage of MRSA before the
AST. For ﬁve out of 14 patients (35.7%) receiving unnecessary
use of glycopeptides for MSSA in the intervention group, the
rapid detection of MSSA with GeneXpert allowed the
introduction of a b-lactam treatment before the availability
of a routine AST that needed an overnight incubation.
(Table 2).
Toxicity
No skin rashes were documented in either group, although 95%
of patients with empirical MRSA coverage in the control group
and 89% in the intervention group were treated with vancomy-
TABLE 1. Patient characteristics according to intervention
Characteristics
Intervention
n = 106 Control n = 91 p value
Sex (female) 32 (30.2) 27 (29.7) 1.0
Age (median/range, years) 66/0–94 67/0–93 0.4
ICU stay before bacteraemia 16 (15.1) 12 (13.2) 0.68
Nosocomial bacteraemia 50 (47.2) 49 (53.8) 0.39
Source of bacteraemia
Intravascular catheter 37 (34.9) 32 (35.2) 1.0
Skin and soft tissue infection 28 (26.4) 27 (29.7) 0.22
Others 16 (15.1) 21 (23.1) 0.2
Unknown 25 (23.6) 11 (12.1) 0.04
Severe sepsis/septic shock 11 (10.4) 9 (9.9) 0.82
Known MRSA carrier 19 (17.9) 17 (18.7) 1.0
Immunosuppression 25 (23.6) 21 (23.1) 1.0
Diabetes 31 (29.2) 28 (30.8) 0.88
IDU 4 (3.8) 5 (5.5) 0.74
Dialysis 9 (8.5) 4 (4.4) 0.39
Penicillin allergy 10 (9.4) 5 (5.5) 0.42
Bacteraemias due to MRSA 24 (22.6) 19 (20.9) 0.86
ID consultation 97 (91.5) 84 (92.3) 1.0
Adequate empirical therapy 100 (94.3) 86 (94.5) 1.0
Complicated bacteraemia 32 (30.2) 29 (31.9) 0.88
Data are n (%), unless stated otherwise.
ICU, intensive care unit; IDU, injecting drug user; ID, infectious diseases; MRSA,
methicillin-resistant Staphylococcus aureus.
Intervention n = 106 Control n = 91
MRSA MSSA MRSA MSSA
Empirical anti-MRSA tx, all 22/24 (91.7) 14/82 (17.1)* 18/19 (94.7) 21/72 (29.2)*
Empirical anti-MRSA tx, without PA 20/22 (90.9) 6/74 (8.1)** 16/17 (94.1) 18/69 (26.1)**
Data are n (%).MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus ; PA,
penicillin allergy; Tx, treatment.
*p 0.09, **p 0.01 (Fisher’s exact test).
Empirical anti-MRSA treatment = prescription of glycopeptides or daptomycin.
TABLE 2. Impact of the GeneXpert
MRSA performed directly on posi-
tive blood cultures on the empirical
antibiotic therapy
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cin. Regarding renal insufﬁciency, there was no statistically
signiﬁcant difference in rates of renal insufﬁciency between the
intervention group and the control group at day 3 (0% versus
3.2%), day 7 (9.4% versus 4.4%) or day 14 (7.5% versus 6.6%).
Discussion
In this prospective, randomized interventional study including
197 patients with S. aureus bacteraemia, we documented a
very high reliability of GeneXpert performed directly on blood
cultures in diagnosing methicillin resistance, as 99% of cases
were correctly diagnosed hours before the routine AST.
Contrary to data from our own centre established in a
prospective study of S. aureus carriage, in which 12.9% of
patients were wrongly identiﬁed as MRSA carriers using
GeneXpert MRSA performed on screening swabs [20], we did
not document false-positive tests with this assay when it was
applied to blood cultures. High levels of performance have
already been reported by groups performing this molecular
diagnosis directly on positive blood cultures with gram-positive
cocci in clusters [16–18]. As the excellent performances of
MALDI-TOF MS for the identiﬁcation of S. aureus in blood
cultures were also conﬁrmed in a real-life setting, we think that
the combination of both techniques would help to spare using
the expensive GeneXpert test in cases of coagulase-negative
staphylococci, which are often contaminants.
Appropriate empirical antibiotic therapy remains the most
critical determinant of prognosis for patients with bloodstream
infections [6,21]. In patients with severe sepsis, as was the case
in 10% of our patients, time to initiation of an effective
antibiotic therapy predicted the risk of death, as each hour of
delay was associated with a signiﬁcant decrease in survival [22].
In the setting of S. aureus bacteraemia, delay until effective
treatment (e.g. absence of MRSA coverage when indicated)
was associated with increased mortality and longer hospital
stay [23]. Hence, reducing the time to result is critical in
clinical microbiology. As the standard of blood culture
management [7], Gram stain reporting had a major impact
on empirical antibiotic therapy and improvement of its
turnaround time was associated with improvement of patient
prognosis [24]. More recently, routine application of MALDI-TOF
MS on blood cultures was associated with an 11% increase in the
appropriateness of an empirical antibiotic regimen, although this
study was not designed to assess mortality [25].
Data on the clinical impact of PCR-based diagnosis of
methicillin resistance are scarce. Bauer et al. [26] demonstrated
in a single-centre study performed in a high-incidence environ-
ment that molecular diagnosis produced a possible decrease in
the mean length of stay of >6 days and so decreased hospital
costs. In another setting of 20% resistance to methicillin among
S. aureus, the use of GeneXpert was associated with 54% earlier
appropriate vancomycin prescription in patients with MRSA
bacteraemia and 25% avoidance of unnecessary use of vanco-
mycin [27]. As most patients with MRSA bacteraemia in our
study were previously known carriers, adequate coverage was
already provided to most of them before obtaining the
GeneXpert result. The use of GeneXpert allowed us to spare
unnecessary prescriptions of anti-MRSA agents, especially in the
subgroup of patients without penicillin allergy (although other
confounding factors might exist), and allowed us to introduce
an earlier adequate coverage in the few unsuspected cases.
This may be of greater value in settings with higher incidence
of community-associated MRSA, which remains very low in
Switzerland. Furthermore, this highly speciﬁc test allowed us
to adequately prescribe b-lactams in the few MRSA carriers
with MSSA bacteraemia. This may be useful given the higher
efﬁcacy of b-lactams [28,29], although the cost-effectiveness of
such a strategy should be evaluated.
In conclusion, we have documented highly successful perfor-
mance of GeneXpert for the diagnosis of methicillin resistance of
S. aureus in blood culture. Our work therefore emphasizes
the usefulness of coupling rapid PCR on blood cultures to
MALDI-TOF MS identiﬁcation in clinical practice. These results
should nowbe conﬁrmed in larger studies also investigating clinical
outcomes and including a cost-effectiveness analysis as well as in
settings of higher MRSA incidence, where the combination of
MALDI-TOF MS with GeneXpert MRSA should be of signiﬁcant
help in improving the management of S. aureus bacteraemia.
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